secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sunshine Biopharma Inc. (SBFM)
CIK:        0001402328
Form:       8-K
Filed at:   2024-10-23T23:59:59+00:00
Accession:  0001683168-24-007323
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sunshine Biopharma enters new employment agreements with CEO, CFO, COO; CEO severance of $14M USD
--------------------------------------------------------------------------------

- CEO Dr. Slilaty: $543,753 CAD base salary, 5% or CPI annual increase, $14M USD severance for termination without cause or for good reason.
- CFO Camille Sebaaly: $411,000 CAD base salary, 5% or CPI annual increase, $2M CAD severance for termination without cause.
- COO Dr. Merzouki: $328,800 CAD base salary, 5% or CPI annual increase, $2M CAD severance for termination without cause.
- All three executives to devote 90% of time to subsidiary Nora Pharma Inc.; agreements effective retroactive to January 1, 2024.
- CEO's $14M USD severance is substantially larger relative to base salary than CFO and COO severance of $2M CAD each.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824007323/0001683168-24-007323-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1402328/000168316824007323/sunshine_8k.htm
  HTML page:      https://secwatch.observer/filing/0001683168-24-007323

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer